Double agents in the war on cancer: leukocytes govern ovarian cancer progression.
Publication
, Journal Article
Scarlett, UK; Conejo-Garcia, JR
Published in: Oncotarget
March 2012
In conclusion, our work expands our understanding of tumor progression and provides further mechanistic rationale to develop novel interventions targeting immunosuppression. Future studies should unveil other unrecognized aspects of the contribution of the immune system to cancer prevention and progression.
Duke Scholars
Published In
Oncotarget
DOI
EISSN
1949-2553
Publication Date
March 2012
Volume
3
Issue
3
Start / End Page
226 / 227
Location
United States
Related Subject Headings
- Tumor Escape
- Ovarian Neoplasms
- Neoplasms
- Leukocytes
- Humans
- Female
- Disease Progression
- Carcinoma
- Adaptive Immunity
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Scarlett, U. K., & Conejo-Garcia, J. R. (2012). Double agents in the war on cancer: leukocytes govern ovarian cancer progression. Oncotarget, 3(3), 226–227. https://doi.org/10.18632/oncotarget.478
Scarlett, Uciane K., and Jose R. Conejo-Garcia. “Double agents in the war on cancer: leukocytes govern ovarian cancer progression.” Oncotarget 3, no. 3 (March 2012): 226–27. https://doi.org/10.18632/oncotarget.478.
Scarlett UK, Conejo-Garcia JR. Double agents in the war on cancer: leukocytes govern ovarian cancer progression. Oncotarget. 2012 Mar;3(3):226–7.
Scarlett, Uciane K., and Jose R. Conejo-Garcia. “Double agents in the war on cancer: leukocytes govern ovarian cancer progression.” Oncotarget, vol. 3, no. 3, Mar. 2012, pp. 226–27. Pubmed, doi:10.18632/oncotarget.478.
Scarlett UK, Conejo-Garcia JR. Double agents in the war on cancer: leukocytes govern ovarian cancer progression. Oncotarget. 2012 Mar;3(3):226–227.
Published In
Oncotarget
DOI
EISSN
1949-2553
Publication Date
March 2012
Volume
3
Issue
3
Start / End Page
226 / 227
Location
United States
Related Subject Headings
- Tumor Escape
- Ovarian Neoplasms
- Neoplasms
- Leukocytes
- Humans
- Female
- Disease Progression
- Carcinoma
- Adaptive Immunity
- 3211 Oncology and carcinogenesis